Individuals who do not meet the criteria for participation in this trial (screen failure) because of a transient lab abnormality may be rescreened. 2.3.2 Treatment Assignment Procedures Cohorts Number Name Description 1 Cohort 1 Subjects with HPV associated malignancies 2 Cohort 2 Subjects with cervical cancer with prior pelvic radiation and boost brachytherapy 2 Arms Number Name Description 1 Arm 1 HPV vaccine + NHS -IL12 + M7824 2 Arm 2 HPV vaccine + NHS -IL12 + M7824 at reduced doses Arm Assignment Participants in Cohort 1 will be assigned to Arm 1, and patients in Cohort 2 will be assigned to Arm 2 . If more than three of eight patients have an objective response then accrual will be expanded to enroll 20 evaluable participants for cohort 1, while cohort 2 may enroll up to 12 patients for a safety evaluation and up to 12 additional patients for preliminary evaluation of efficacy as well as further evaluation of safety 35 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 2.4 BASELINE EVALUATION All subjects are required to complete baseline evaluations within one week prior to the first planned dosing of the study drug (any screening evaluation done within this time period can also serve for the baseline evaluation) : • Physical exam including weight, ECOG performance status and vital signs. • Concomitant Medications and Baseline Signs and Symptoms evaluation.